Bioscience

New Haven-based BioXcel Therapeutics Inc. said it has completed a stock offering that raised about $8 million from an institutional investor.

A state fund that has backed more than 100 Connecticut bioscience startups since 2013 is running low on capital — and lawmakers are weighing whether to refill it.

Intensity Therapeutics, Inc., a Shelton-based biotechnology company, has regained compliance with Nasdaq listing requirements, about three weeks...

New Haven-based Rallybio Corp.’s proposed merger with San Diego biotech Candid Therapeutics includes a potential $50 million breakup fee payable by Candid.

New Haven-based Rallybio Corp. has agreed to merge with a San Diego biotechnology company in a deal backed by more than $505 million in new investor financing that will effectively end Rallybio’s run as a standalone public company.

A Woodbridge-based biotech company has reserved space on the next commercial space station as it works to scale manufacturing of an artificial retina designed to restore vision in patients afflicted with degenerative eye diseases.

Intensity Therapeutics Inc., a Shelton-based biotechnology company, said its board has approved a 1-for-25 reverse stock split of the company’s common stock.

New Haven-based Arvinas Inc. on Thursday named longtime executive Randy Teel as its new president and chief executive officer, succeeding John Houston, who is retiring after nearly a decade leading the biotechnology company.

New Haven-based Precipio Inc., a cancer diagnostics company, recently reported to federal authorities a data breach that occurred in November and possibly affected more than 500 people.

New Haven-based Trevi Therapeutics has raised more than $250 million to develop Haduvio, the only drug in development for chronic cough, with the company preparing Phase 3 trials targeting patients with idiopathic pulmonary fibrosis who cough thousands of times daily.